125 related articles for article (PubMed ID: 20025567)
1. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects.
Marra M; Abbruzzese A; Addeo R; Del Prete S; Tassone P; Tonini G; Tagliaferri P; Santini D; Caraglia M
Curr Cancer Drug Targets; 2009 Nov; 9(7):791-800. PubMed ID: 20025567
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid - a multiplicity of anti-cancer action.
Yuasa T; Kimura S; Ashihara E; Habuchi T; Maekawa T
Curr Med Chem; 2007; 14(20):2126-35. PubMed ID: 17691952
[TBL] [Abstract][Full Text] [Related]
3. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates.
Santini D; Caraglia M; Vincenzi B; Holen I; Scarpa S; Budillon A; Tonini G
Nat Clin Pract Oncol; 2006 Jun; 3(6):325-38. PubMed ID: 16757970
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid: an unending tale for an antiresorptive agent.
Caraglia M; Marra M; Naviglio S; Botti G; Addeo R; Abbruzzese A
Expert Opin Pharmacother; 2010 Jan; 11(1):141-54. PubMed ID: 20001436
[TBL] [Abstract][Full Text] [Related]
7. Direct antitumour activity of zoledronic acid: preclinical and clinical data.
Bosch-Barrera J; Merajver SD; Menéndez JA; Van Poznak C
Clin Transl Oncol; 2011 Mar; 13(3):148-55. PubMed ID: 21421459
[TBL] [Abstract][Full Text] [Related]
8. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
Salzano G; Marra M; Porru M; Zappavigna S; Abbruzzese A; La Rotonda MI; Leonetti C; Caraglia M; De Rosa G
Int J Pharm; 2011 Jan; 403(1-2):292-7. PubMed ID: 21055454
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases.
Chen T; Berenson J; Vescio R; Swift R; Gilchick A; Goodin S; LoRusso P; Ma P; Ravera C; Deckert F; Schran H; Seaman J; Skerjanec A
J Clin Pharmacol; 2002 Nov; 42(11):1228-36. PubMed ID: 12412821
[TBL] [Abstract][Full Text] [Related]
11. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.
Caraglia M; D'Alessandro AM; Marra M; Giuberti G; Vitale G; Viscomi C; Colao A; Prete SD; Tagliaferri P; Tassone P; Budillon A; Venuta S; Abbruzzese A
Oncogene; 2004 Sep; 23(41):6900-13. PubMed ID: 15286715
[TBL] [Abstract][Full Text] [Related]
12. New role for an established drug? Bisphosphonates as potential anticancer agents.
Koul HK; Koul S; Meacham RB
Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):111-9. PubMed ID: 21876554
[TBL] [Abstract][Full Text] [Related]
13. Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells.
Insalaco L; Di Gaudio F; Terrasi M; Amodeo V; Caruso S; Corsini LR; Fanale D; Margarese N; Santini D; Bazan V; Russo A
J Cell Mol Med; 2012 Sep; 16(9):2186-95. PubMed ID: 22260151
[TBL] [Abstract][Full Text] [Related]
14. Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.
Qiao H; Wang TY; Yu ZF; Han XG; Liu XQ; Wang YG; Fan QM; Qin A; Tang TT
Cell Death Dis; 2016 Feb; 7(2):e2094. PubMed ID: 26866274
[TBL] [Abstract][Full Text] [Related]
15. Tumour macrophages as potential targets of bisphosphonates.
Rogers TL; Holen I
J Transl Med; 2011 Oct; 9():177. PubMed ID: 22005011
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory and necrotic effects of minodronate, a nitrogen-containing bisphosphonate, in mice.
Kiyama T; Okada S; Tanaka Y; Kim S; Bando K; Hasegawa M; Yamaguchi K; Takano-Yamamoto T; Sasaki K; Sugawara S; Endo Y
Tohoku J Exp Med; 2013 Jul; 230(3):141-9. PubMed ID: 23822921
[TBL] [Abstract][Full Text] [Related]
17. The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway.
Wilson C; Ottewell P; Coleman RE; Holen I
BMC Cancer; 2015 Feb; 15():55. PubMed ID: 25884855
[TBL] [Abstract][Full Text] [Related]
18. Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs?
Santini D; Schiavon G; Angeletti S; Vincenzi B; Gasparro S; Grilli C; La Cesa A; Virzí V; Leoni V; Budillon A; Addeo SR; Caraglia M; Dicuonzo G; Tonini G
Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):383-96. PubMed ID: 18221048
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.
Fournier P; Boissier S; Filleur S; Guglielmi J; Cabon F; Colombel M; Clézardin P
Cancer Res; 2002 Nov; 62(22):6538-44. PubMed ID: 12438248
[TBL] [Abstract][Full Text] [Related]
20. The backbone of progress--preclinical studies and innovations with zoledronic acid.
Green JR; Guenther A
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S3-S12. PubMed ID: 21353178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
